Novo Nordisk A/S (NYSE:NVO) Shares Up 5.5% – Still a Buy?

Novo Nordisk A/S (NYSE:NVO)’s share price traded up 5.5% during trading on Tuesday . The stock traded as high as $79.57 and last traded at $79.64. 4,638,015 shares traded hands during trading, a decline of 33% from the average session volume of 6,915,415 shares. The stock had previously closed at $75.46.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an “underperform” rating on the stock. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $128.00.

Novo Nordisk A/S Trading Up 5.6%

The business’s 50-day simple moving average is $66.01 and its two-hundred day simple moving average is $80.18. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $357.71 billion, a price-to-earnings ratio of 24.24, a PEG ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Trading of Novo Nordisk A/S

A number of large investors have recently modified their holdings of the stock. Center for Financial Planning Inc. boosted its stake in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its stake in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Copeland Capital Management LLC grew its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Finally, Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.